FDA approves new diagnostic imaging agent to detect recurrent prostate cancer
The FDA approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for PET imaging in men with suspected prostate cancer recurrence based on elevated prostate specific antigen levels following prior treatment. Axumin is marketed by Blue Earth Diagnostics, Oxford, UK. May 27, 2016